[N-{(4R)-4-Carboxy-Κo-4-[4,7,10-Tris(Carboxy-Κ3O4,O7,O10-Methyl)-1,4,7,10-Tetraazacyclododecan-1-Yl-Κ4N1,N4,N7,N10]Butanoyl}-3-Iodo-D-Tyrosyl-D-Phenylalanyl-N6-(8-{N2-[(L-Glutamic Acid-N-Yl)Carbonyl]-L-Lysin-N6-Yl}-8-Oxooctanoyl)-D-Lysinato(3−)](177Lu)Lutetium

1 trials

Filter these 1 trials by condition, phase, country and more.

Open in Search →

1 Registered trials

0 Recruiting

1 Completed trials

1 Sponsors

3 Countries

Phase III

Phase III: 1

Sponsors using this IMP

Point Biopharma Inc. 1

All trials

1 total

Lutetium after second-line hormonal treatment [PBP-301] [SPLASH] Ended

2024-515604-39-00 Phase III 3 countries Point Biopharma Inc.

Showing 1–1 of 1 trials

← All drugs A–Z